FrancophonIA/ELRC3.0 huggingface dataset:
English: What benefits of Esmya have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Esmya kasulikkus?
English: In some women, progesterone may promote the growth of fibroids, which can cause symptoms such as heavy uterine bleeding (bleeding from the womb during or outside the menstrual period), anaemia (low red blood cell counts, due to bleeding) and abdominal pain (such as period pain).
Estonian: Mõnel naisel võib progesteroon soodustada emakafibroidide kasvu, mis võib põhjustada selliseid sümptomeid nagu tugev emakaverejooks menstruatsiooni ajal või menstruatsioonidevahelisel perioodil, aneemia (erütrotsüütide (vere punaliblede) vähesus, verejooksu tõttu) ja kõhuvalu (näiteks menstruatsiooniaegne valu).
English: Uterine fibroids are non-cancerous (benign) tumours of the womb (uterus).
Estonian: Emakafibroidid on emaka mittekantseroossed (healoomulised) kasvajad.
English: The size of the fibroids was also smaller in women treated with Esmya than in those who received placebo.
Estonian: Ka emakafibroidide mõõtmed olid Esmyaga ravitud naistel väiksemad kui platseeborühma naistel.
English: The active substance in Esmya, ulipristal acetate, blocks the activity of progesterone, a hormone in the body involved in controlling the growth of the lining of the womb.
Estonian: Esmya toimeaine ulipristaalatsetaat blokeerib emaka limaskesta kasvu reguleeriva hormooni progesterooni toimet.
English: • as a single treatment course in women before they have surgery for their fibroids;
Estonian: • ühekordse ravikuurina naistele enne emakafibroidide operatsiooni ja
English: An overview of Esmya and why it is authorised in the EU
Estonian: Ülevaade ravimist Esmya ja ELis müügiloa väljastamise põhjendus
English: Esmya has been shown to be effective in reducing symptoms as well as the size of the fibroids in women who were to have surgery for their fibroids and when used intermittently for longer periods (up to 4 treatment courses).
Estonian: Tõendati, et Esmya on efektiivne fibroidide põhjustatud sümptomite ja fibroidide mõõtmete vähendamisel, kui ravimit kasutatakse naistel, keda tuleb opereerida, vahelduvate ravikuuridena (kuni 4 ravikuuri) pikema aja vältel.
English: How is Esmya used?
Estonian: Kuidas Esmyat kasutatakse?
English: • as intermittent treatment for women in whom surgery is not suitable.
Estonian: • korduva vaheaegadega ravina naistele, kellele operatsioon ei ole näidustatud.
English: When progesterone activity is blocked, fibroid cells stop dividing and eventually die, which reduces the size of the fibroids and the symptoms caused by them.
Estonian: Kui progesterooni toime on blokeeritud, ei jagune emakafibroidide rakud enam ja lõpuks hävivad.
English: In the second study, Esmya taken for three months was as effective as leuprorelin (another medicine for fibroids) in reducing heavy uterine bleeding, with bleeding reduced in 90% of women treated with Esmya compared with 89% of women treated with leuprorelin.
Estonian: Teises uuringus vähendas 3-kuuline Esmya-ravi tugevat emakaverejooksu sama efektiivselt kui leuproreliin (samuti emakafibroidide ravim): vähenenud emakaverejooksuga patsiente oli Esmya rühmas 90% ja leuproreliini rühmas 89% patsientidest.
English: Esmya is a medicine used to treat moderate to severe symptoms of uterine fibroids in adult women who have not yet reached the menopause.
Estonian: Esmyat kasutatakse emakafibroidide mõõdukate kuni raskete sümptomite raviks menopausieelses eas täiskasvanud naistel.
English: In the first study, uterine bleeding was reduced in 92% of women taking Esmya for three months (one treatment course) compared with 19% of women taking placebo (a dummy treatment).
Estonian: Esimeses uuringus oli naisi, kellel emakaverejooks vähenes, Esmyat 3 kuud (üks ravikuur) võtnud naistest 92% ja platseebot (näiv ravim) võtnud naistest 19%.
English: What are the risks associated with Esmya?
Estonian: Mis riskid Esmyaga kaasnevad?
English: For the full list of all side effects reported with Esmya, see the package leaflet.
Estonian: Esmya kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Esmya can only be obtained with a prescription, and treatment should be started and supervised by a doctor experienced in the diagnosis and treatment of uterine fibroids.
Estonian: Ravi sellega peab alustama ja jälgima emakafibroidide diagnoosimises ja ravis kogenud arst.
English: Rare but serious cases of liver injury have been reported with the medicine and measures have been put in place to minimise this risk.1 Although endometrial thickening was seen in some patients, it normally disappeared after stopping treatment.
Estonian: Kuigi mõnel patsiendil täheldati endomeetriumi paksenemist, kadus see tavaliselt ravi peatamisel.
English: MA (EU) Number (Invented) name Strength Pharmaceutical form Route of administration Immediate Packaging Pack size blister (PVC/alu)
Estonian: Blisterpakend (PVC/alumiinium)
English: They were authorised through national approval procedures under various trade names (Bioparox, Fusaloyos, Locabiotal and Locabiosol) in the following countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Portugal, Romania, Slovakia and Spain.
Estonian: Need kiideti heaks riiklike menetlustega mitme kaubandusliku nimetuse all (Bioparox, Fusaloyos, Locabiotal ja Locabiosol) järgmistes liikmesriikides: Austria, Belgia, Bulgaaria, Eesti, Hispaania, Iirimaa, Itaalia, Kreeka, Küpros, Leedu, Läti, Luksemburg, Malta, Portugal, Rumeenia, Saksamaa, Slovakkia, Tšehhi Vabariik ja Ungari.
English: Fusafungine-containing medicines have been available in several EU countries for over 50 years.
Estonian: Fusafungiini sisaldavaid ravimeid on turustatud mitmes Euroopa Liidu liikmesriigis juba üle 50 aasta.
English: 1 April 2016 EMA/227560/2016
Estonian: 1. aprill 2016 EMA/227560/2016
English: Although the review found that serious allergic reactions are rare, they can be life-threatening and no measures have been identified to sufficiently reduce or manage this risk.
Estonian: Kuigi läbivaatamisel leiti, et rasked allergilised reaktsioonid esinevad harva, võivad need olla eluohtlikud ja selle riski piisava vähendamise või haldamise meetmeid ei ole tuvastatud.
English: The review of fusafungine-containing medicines was initiated on 11 September 2015 at the request of Italy, under Article 31 of Directive 2001/83/EC.
Estonian: 11. septembril 2015 algatati Itaalia taotlusel fusafungiini sisaldavate ravimite direktiivi 2001/83/EÜ artikli 31 kohane hindamine.
English: • Healthcare professionals should advise patients on alternative treatments, if needed.
Estonian: • Vajaduse korral peavad tervishoiutöötajad soovitama patsientidele muid ravimeid.
English: Medicines to be withdrawn due to serious allergic reactions and limited evidence of benefit
Estonian: Ravimid tuleb turult kõrvaldada raskete allergiliste reaktsioonide ja kasulikkuse piiratud tõendite tõttu
English: This follows a review by EMA's Pharmacovigilance Risk Assessment Committee (PRAC) which concluded that the benefits of fusafungine do not outweigh its risks, particularly the risk of serious allergic reactions.
Estonian: Otsus tehti Euroopa Ravimiameti (EMA) ravimiohutuse riskihindamise komitee läbivaatamise tulemuste alusel, milles järeldati, et fusafungiini kasulikkus ei ületa riske, eelkõige raskete allergiliste reaktsioonide riski.
English: In some Member States, these medicines were available without prescription.
Estonian: Mõnes liikmesriigis turustati neid ravimeid käsimüügiravimitena.
English: • Patients with any questions should speak to their healthcare professional.
Estonian: • Küsimuste korral peab patsient pöörduma meditsiinitöötaja poole.
English: The benefit-risk balance for fusafungine-containing medicines is therefore negative for all currently authorised uses.
Estonian: Fusafungiini sisaldavate ravimite kasulikkuse ja riski suhe on seepärast kõigil praegu heakskiidetud näidustusel negatiivne.
English: In addition, there were concerns about the potential for fusafungine to promote antibiotic resistance (the ability of bacteria to grow in the presence of an antibiotic that would normally kill them or limit their growth).
Estonian: Samuti tekitas ettevaatlikkust võimalus, et fusafungiin suurendab antibiootikumiresistentsust (bakterite võimet paljuneda sellise antibiootikumi juuresolekul, mis need tavaliselt hävitaks või piiraks nende paljunemist).
English: The CMDh is a regulatory body representing EU Member States as well as Iceland, Liechtenstein and Norway.
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühm on Euroopa Liidu liikmesriike ning Islandit, Liechtensteini ja Norrat esindav regulatiivorgan.
English: • Upper airway infections are usually mild and self-limiting.
Estonian: • Ülemiste hingamisteede infektsioonid on tavaliselt kerge kuluga ja iseparanevad.
English: • These sprays are being taken off the market in the EU because of rare cases of serious allergic reactions and the lack of strong evidence that these medicines work.
Estonian: • Need spreid kõrvaldatakse Euroopa Liidu turult harvaesinevate raskete allergiliste reaktsioonide ja ebapiisavate ravimi efektiivsust tõendavate andmete tõttu.
English: During its review the PRAC consulted EMA's paediatric scientific committee as well as experts in the field of anti-infective medicines.
Estonian: Ravimiohutuse riskihindamise komitee konsulteeris läbivaatamise ajal EMA teadusliku pediaatriakomitee ja infektsioonivastaste ravimite ekspertidega.
English: As fusafungine-containing medicines are all authorised nationally, the PRAC recommendations were forwarded to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), which adopted a final position on 31 March 2016.
Estonian: Et kõik fusafungiini sisaldavad ravimid on saanud müügiloa riiklike menetluste kaudu, saadeti ravimiohutuse järelevalve riskihindamiskomitee soovitused inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühmale, kes võttis vastu lõpliku seisukoha 31. märtsil
English: Following the CMDh consensus position, EU Member States will start revoking the marketing authorisations of these medicines in their territories, according to an agreed timetable.
Estonian: Kooskõlastusrühma konsensusliku seisukoha alusel alustavad Euroopa Liidu liikmesriigid nende ravimite müügilubade tagasivõtmist oma territooriumil vastavalt kokkulepitud ajakavale.
English: The review has been carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Estonian: Teabe vaatas läbi inimravimite ohutusprobleemide hindamise eest vastutav ravimiohutuse riskihindamise komitee, kes koostas soovitused.
English: Serious allergic reactions have occurred soon after the use of these sprays and involved bronchospasm (excessive and prolonged contractions of the airway muscles leading to difficulty breathing).
Estonian: Vahetult pärast nende spreide kasutamist on esinenud raskeid allergilisi reaktsioone, sh bronhospasme (hingamisteede lihaste liigsed ja pikaaegsed krambid, mis põhjustavad hingamisraskusi).
English: Fusafungine is an antibiotic and anti-inflammatory medicine used in the form of a nasal and oromucosal (to be applied to the mouth) spray for the treatment of the following infections of the upper airways: sinusitis (sinus infection), rhinitis (stuffy and runny nose), rhinopharyngitis (common cold), tonsillitis (inflammation of the tonsils caused by an infection) and laryngitis (inflammation of the voice box).
Estonian: Fusafungiin on antibiootikum ja põletikuvastane ravim, mida kasutatakse suu- ja ninaõõnespreina ülemiste hingamisteede järgmiste infektsioonide raviks: sinusiit (ninakõrvalurke infektsioon), riniit (ninakinnisus ja ninavoolus), rinofarüngiit (tavaline nohu), tonsilliit (infektsioonist põhjustatud kurgumandlipõletik) ja larüngiit (kõripõletik).
English: With regard to the benefits, the evidence for beneficial effects of fusafungine is weak.
Estonian: Tõendid fusafungiini kasuliku toime kohta on nõrgad.
English: Although there is insufficient evidence to establish that fusafungine can increase the risk of resistance, this risk could not be ruled out.
Estonian: Kuigi fusafungiini resistentsust suurendava toime kohta ei ole piisavalt tõendeid, ei saa seda riski siiski välistada.
English: As the CMDh adopted its position by consensus, the measures recommended by the PRAC will be implemented directly by the Member States where the medicines are authorised, according to an agreed timetable.
Estonian: Et kooskõlastusrühm võttis seisukoha vastu konsensuse alusel, rakendavad liikmesriigid, kus ravimid on heaks kiidetud, riskihindamiskomitee soovitatud meetmed vahetult ja kokkulepitud ajakava järgi.
English: Taking into account the mild and self-limiting nature of upper airway infections such as rhinopharyngitis, the benefits of fusafungine were not considered to outweigh the risks.
Estonian: Kuivõrd ülemiste hingamisteede infektsioonide (nt rinofarüngiidi) kulg on kerge ja iseparanev, ei peetud fusafungiini kasulikkust riskideks suuremaks.
English: Fusafungine is an antibiotic and anti-inflammatory nose and mouth spray used to treat upper airway infections such as rhinopharyngitis (common cold).
Estonian: Fusafungiin on antibiootiline ja põletikuvastane nina- ja suuõõnesprei, millega ravitakse ülemiste hingamisteede infektsioone, näiteks rinofarüngiiti (tavaline nohu).
English: • Fusafungine nose and mouth sprays have been used to treat upper airway infections.
Estonian: • Fusafungiini nina- ja suuõõnespreisid on kasutatud ülemiste hingamisteede infektsioonide raviks.
English: The CMDh1 has endorsed by consensus the revocation of marketing authorisations for fusafungine sprays in the EU.
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühm1 kiidab konsensuse alusel heaks fusafungiini spreide müügilubade tühistamise Euroopa Liidus.
English: [the below currently approved indications should be deleted (specific wording of the indication may vary from product to product)]
Estonian: 4.1 Näidustused [allolevad praegu heakskiidetud näidustused tuleks kustutada (konkreetse näidustususe sõnastus võib ravimitel erineda)]
English: B. Package Leaflet
Estonian: B. PAKENDI INFOLEHT
English: • Symptomatic treatment of veno-lymphatic insufficiency All references to the above mentioned indications should be deleted from the remaining relevant sections of the summaries of product characteristics.
Estonian: • Veeni-lümfisüsteemi puudulikkuse sümptomaatiline ravi Ravimi omaduste kokkuvõtte vastavatest lõikudes tuleks kustutada kõik viited ülalmainitud näidustustele.
English: A. Summary of Product Characteristics
Estonian: A. RAVIMI OMADUSTE KOKKUVÕTE
English: 21 February 2006 EMEA/CHMP/373083/2005
Estonian: 21. veebruar 2006 EMEA/CHMP/373083/2005
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Lansoprazol AbZ-Pharma 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole
Estonian: INIMTERVISHOIUS KASUTATAVATE RAVIMITE KOMITEE (CHMP) ARVAMUS PÄRAST ARTIKLI 29 LÕIKE 21 JÄRGSET ESILDIST Lansoprazol AbZ-Pharma 15 mg ja 30 mg Rahvusvaheline mittekaubanduslik nimetus (INN): lansoprasooli
English: A Marketing Authorisation for Lansoprazol AbZ-Pharma (15 mg and 30 mg) was previously granted to ratiopharm GmbH in Finland on 7 November 2003.
Estonian: Ratiopharm GmbHle väljastati Lansoprazol AbZ-Pharma (15 mg ja 30 mg) müügiluba Soomes 7. novembril 2003.
English: During its September 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lansoprazol AbZ-Pharma.
Estonian: Tuginedes kõigile esitatud andmetele ja komitee sisesele arutelule, jõudis inimtervishoius kasutatavate ravimite komitee oma 2005. aasta septembri koosolekul seisukohale, et Lansoprazol AbZ-Pharmai riski ja kasu vahekord on soodne.
English: Lansoprazol AbZ-Pharma (lansoprazole) is a proton pump inhibitor that inhibits gastric acid secretion and is used for treatment of duodenal and gastric ulcer, reflux oesophagitis, gastro-oesophageal reflux disease, treatment and prophylaxis of NSAID-associated gastric and duodenal ulcers, Zollinger-Ellison syndrome, and in combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with H. pylori associated ulcers.
Estonian: Lansoprasooli kasutatakse kaksiksõrmiksoole ja maohaavandite, refluksösofagiidi, gastroösofageaalse reflukshaiguse raviks, mittesteroidsete põletikuvastaste ravimitega seotud mao- ja kaksteistsõrmikuhaavandite ja Zollinger-Ellisoni sündroomi raviks ja profülaktikaks.
English: EU/1/19/1389/001 Epidyolex 100 mg/mL Oral Solution
Estonian: EU/1/19/1389/001 Epidyolex
English: 1 bottle + 2 syringes of 1 ml + 2 syringes of 5 ml + 2 bottle adaptors
Estonian: 1 pudel + 2 suusüstalt 1 ml +
English: 100 ml
Estonian: Pudel (klaas) 100 ml
English: Then go on as before.
Estonian: Edasi jätkake nii nagu enne.
English: (your body is not producing any urine)
Estonian: (teie organism ei produtseeri üldse uriini),
English: Do not chew or crush them.
Estonian: Ärge närige või purustage neid.
English: • if you suffer from diabetic autonomic neuropathy, a disease associated with diabetes which affects your nervous system.
Estonian: • kui teil on diabeetiline autonoomne neuropaatia, diabeediga kaasnev haigus, mis kahjustab teie närvisüsteemi.
English: PVC/PVDC/aluminium blister pack.
Estonian: PVC/PVDC/alumiiniumist blisterpakend.
English: Choose a time that is convenient and take your tablet at this time each day.
Estonian: Valige üks aeg, mis sobib igal päeval tablettide võtmiseks.
English: Taking too many tablets at once can make you feel unwell.
Estonian: Kui võtate korraga liiga palju tablette võite end haiglaselt tunda.
English: Winthrop Arzneimittel GmbH Industriestrasse 10 82256 Furstenfeldbruck Germany
Estonian: Winthrop Arzneimittel GmbH Industriestrasse 10 82256 Furstenfeldbruck Saksamaa
English: If you take too many tablets, tell your doctor immediately or go to the nearest hospital casualty department.
Estonian: Kui võtate tablette liiga palju, rääkige sellest kohe oma arstile või minge lähimasse erakorralise meditsiini osakonda.
English: Do not use after the expiry date which is stated on the carton.
Estonian: Ärge kasutage pärast kõlblikkusaega, mis on märgitud karbil.
English: Chapeltown Distribution Centre 51 Cart Road, Chapeltown, Sheffield, S35 2PF United Kingdom
Estonian: Chapeltown Distribution Centre 51 Cart Road, Chapeltown, Sheffield, S35 2PF
English: The prolonged-release tablets should not be chewed, divided or crushed.
Estonian: Toimeainet prolongeeritult vabastavaid tablette ei tohi närida, tükeldada ega purustada.
English: Frequencies are defined as very common (≥1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10 000 to <1/1000); very rare (<1/10 000).
Estonian: Esinemissagedused on määratletud järgmiselt: väga sage (≥ 1/10), sage (> 1/100 kuni < 1/10), aeg-ajalt (> 1/1000 kuni < 1/100), harv (> 1/10 000 kuni < 1/1000), väga harv (< 1/10 000).
English: The majority of the adverse reactions were transient.
Estonian: Enamik kõrvaltoimetest olid mööduvad.
English: Pharmacotherapeutic group: Alpha-adrenoceptor antagonists, ATC code: C02CA04
Estonian: Farmakoterapeutiline grupp: alfa-adrenoblokaatorid, ATC-kood: C02CA04
English: • if you are suffering from heart disease
Estonian: • kui teil on südamehaigus,
English: • if you have ever suffered an allergic reaction (e.g. itching, reddening of the skin or difficulty breathing)
Estonian: • kui teil on kunagi esinenud allergiline reaktsioon (nt sügelemine, nahapunetus või hingamisraskused)
English: If you forget to take your tablet, leave the dose out completely.
Estonian: Kui unustate oma tableti võtmata, jätke see annus lihtsalt vahele.
English: • other medicine to lower blood pressure
Estonian: • muud vererõhku langetavat ravimit,
English: Do not change the dose or stop taking your tablets unless you have spoken to your doctor.
Estonian: Ärge muutke annust ega lõpetage tablettide võtmist, kui arst ei ole käskinud teil seda teha.
English: - It is unlikely that the potential differences observed between the reference product and the generic versions influence the information in the Summary of Product Characteristics (SPC).
Estonian: - on vähe tõenäoline, et võimalikud erinevused võrdluspreparaadi ja geneeriliste versioonide vahel mõjutaksid ravimi omaduste kokkuvõtte sisu;
English: Your tablets should be swallowed whole.
Estonian: Tabletid tuleb alla neelata tervelt.
English: • if you have or have had in the past any form of obstruction of the digestive tract.
Estonian: • kui teil on või on varem olnud mingit liiki seedetrakti ummistus,
English: Fax: 0036 1 505 0005
Estonian: Faks 0036 1 505 0005
English: This medicinal product is authorised in the Member States of the EEA under the following names:
Estonian: See ravim on saanud müügiloa EMP liikmesriikides järgmiste nimetuste all [Täidetakse protseduuri lõpetamisel]
English: Winthrop Pharmaceuticals UK Ltd 1 Onslow Street, Guildford, Surrey GU1 4YS United Kingdom
Estonian: Winthrop Pharmaceuticals UK Ltd 1 Onslow Street, Guildford, Surrey GU1 4YS Ühendkuningriik
English: Patients with renal impairment: Since there is no change in pharmacokinetics in patients with impaired renal function, and since there are no signs that doxazosin prolonged release tablets aggravates existing renal impairment, the usual dose can be used in these patients.
Estonian: Neerukahjustusega patsiendid: Kuna neerufunktsiooni kahjustusega patsientidel ravimi farmakokineetikas muutusi ei esine ja kuna ei ole täheldatud, et doksasosiini prolongeeritult vabastavad tabletid halvendaksid olemasolevat neerukahjustust, võib neil patsientidel kasutada tavapäraseid annuseid.
English: cough and cold remedies as they may contain Ephedrine, Phenylephrine.
Estonian: köha ja külmetuse vastaseid ravimeid, sest need võivad sisaldada efedriini ja fenüülefriini.
English: Tell your doctor if you are already taking any of the following:
Estonian: Palun informeerige oma arsti, kui te kasutate mõnda allpool nimetatud ravimitest:
English: Sympathomimetics may reduce the antihypertensive effect of doxazosin; doxazosin may reduce blood pressure and vascular reactions to dopamine, ephedrine, epinephrine, metaraminol, methoxamine and phenylephrine.
Estonian: Sümpatomimeetikumid võivad vähendada doksasosiini hüpertensioonivastast toimet; doksasosiin võib vähendada vererõhku ja veresoonte reaktsiooni dopamiinile, efedriinile, epinefriinile, metaraminoolile, metoksamiinile ja fenüülefriinile.
English: In patients with severe hepatic impairment clinical experience is lacking and therefore the use of doxazosin prolonged release tablets is not recommended (see section 4.4).
Estonian: Raske maksafunktsiooni kahjustusega patsientide ravimise kliiniline kogemus puudub ja seetõttu ei soovitata neil doksasosiini prolongeeritult vabastavaid tablette kasutada (vt lõik 4.4).
English: This effect is thought to result from selective blockade of the alpha-1adrenoceptors located in the vasculature.
Estonian: Arvatakse, et see toime on tingitud veresoontes paiknevate α1adrenoblokaatorite selektiivsest blokaadist.
English: Animal studies have shown reduced foetal survival at high doses (see section 5.3).
Estonian: Loomkatsetes on suurte annuste puhul täheldatud loote elulemuse vähenemist (vt lõik 5.3).
English: • medicine containing Dopamine, Metaraminol, Methoxamine, Adrenaline (Epinephrine)
Estonian: • dopamiini, metaraminooli, metoksamiini, adrenaliini (epinefriini) sisaldavat ravimit,
English: Chinoin Pharmaceuticals and Chemical Works Co Ltd 1045 Budapest, To utca 1-5 HUNGARY Tel: 0036 1 505 0000
Estonian: Chinoin Pharmaceuticals and Chemical Works Co Ltd 1045 Budapest, To utca 1-5 UNGARI